Please login to the form below
Cerdelga
This page shows the latest Cerdelga news and features for those working in and with pharma, biotech and healthcare.
R&D productivity takes off
Among these, notable examples include PTC Therapeutics' Translarna (ataluren) - the first medicine approved for the treatment of Duchenne muscular dystrophy (DMD) - and Sanofi/Genzyme's Cerdelga (eliglustat) for Gaucher disease, a
Latest news
-
Genzyme's oral Gaucher drug cleared in Europe
In contrast, Cerdelga and Zavesca are glucosylceramide synthase inhibitors, which work by reducing the substrate for the deficient enzyme. ... Analysts have suggested Cerdelga could achieve sales upwards of $350m in 2017 and eventually rival Cerezyme in
-
Orphan drugs in latest CHMP recommendations
advisers. The Committee for Medicinal Products for Human Use (CHMP) backed Genzyme's Cerdelga (eliglustat) and Boehringer Ingelheim's Ofev (nintedanib) in its latest round of opinions - which are usually followed ... Cerdelga has demonstrated it is as
-
Sanofi plans 18 new product launches by 2020
The remainder of its growth portfolio are Cerdelga (eliglustat) for Gaucher disease - the only approved oral, first-line therapy for the rare genetic disease, Lemtrada (alemtuzumab) for multiple sclerosis and sarilumab,
-
FDA gives green light to Genzyme’s oral Gaucher drug
the possibility that Cerdelga could be used alongside Cerezyme as a combination regimen. ... The company said it wants a pricing strategy that does not drive patients towards either Cerezyme or Cerdelga, making the choice of therapy a purely clinical
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Deal Watch table for November 2014
Cerdelga (eliglustat) sold by Vertex. Acquisition 75% royalty stream. 66. Five Prime Therapeutics / BMS.
-
Pharma deals during November 2014
In another similar deal, PDL Biopharma acquired the 75% of the University of Michigan's worldwide royalty interest in Cerdelga (eliglustat) for $66m. ... Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Senior Account Manager
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Account Director
-
Competitive
-
Medical Editor
-
Competitive
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- PHE study finds people who have had COVID-19 can still transmit the virus
- PHE study finds people who have had COVID-19 can still transmit the virus
- UK pharmacies to begin administering COVID-19 vaccinations
- New study identifies drugs that are safe to use in COVID-19 treatment
- AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine
- Future-Proofing Healthcare and Medicine
- AI in Computer Vision Technology and the Impact on Healthcare
- Lateral flow tests detect ‘most infectious’ COVID-19 cases, Oxford researchers find
- Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance
- Pfizer/BioNTech's COVID-19 vaccine found to be effective against UK virus variant
- BMS aims for US approval of Opdivo combo in stomach cancer
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- The pandemic preparedness paradox
- Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- Recent years have seen a significant shift in drug development to specialty areas...
- 2020 - a year to remember or forget?
- 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Quick links
Infographics
